Talk to Viviscal: 
The Clinical Trials Process
RESEARCHER
40 females
72 females
15 females
Glynis Ablon, M.D., FAAD, Ablon Skin Institute Research Center, University of California, Los Angeles, California, U.S.A.; and Steven Dayan, M.D., FACS, DeNova Research, Chicago, Illinois, U.S.A.
Thomas J. Stephens & Associates, Inc., Dallas Research Center, Carrollton, Texas, U.S.A.
Glynis Ablon, M.D., FAAD, Ablon Skin Institute Research Center, University of California, Los Angeles, California, U.S.A.
RESULTS
(In progress) 6-month, multi-center, randomized, double-blind, placebo-controlled clinical trial
Hypothesis: ingestion of oral Viviscal supplement will strengthen and promote terminal hairs in female subjects, ages 21-75, who have self-perceived thinning hair
Estimated publication date: summer 2015
6-month double-blind, placebo-controlled clinical trial demonstrated statistically significant results:
- 18.3% reduction in hair shedding vs. placebo
- 7.4% increase in hair thickness vs. placebo
Abstract presented: 7th World Congress for Hair Research (2013; Edinburgh, Scotland)
6-month double-blind, placebo-controlled clinical trial demonstrated statistically significant results:
- 125% increase in terminal hairs vs. placebo group
- Significant, self-perceived improvements in overall hair volume, thickness and scalp coverage
- Published: The Journal of Clinical and Aesthetic Dermatology (Nov. 2012)
- Thomas J. Stephens & Associates, Inc.
- Glynis Ablon, M.D., F.A.A.D., Ablon Skin Institute Reasearch Center, University of California, Los Angeles
- Brook Jackson, M.D., Skin Wellness Center of Chicago
- Thomas J. Stephens & Associates, Inc.
- José Marcos Pereira, M.D., Brazil
Share with us
Pin us
Watch us
Follow us
+ us
Instagram us
Customer Service: 888-444-9073
Email: